Get Trade Alerts

Signup for super-trades.com Free Email List!

Enter your Email


Preview | Powered by FeedBlitz
To subscribe to the Super Stocks Blog by RSS feeder click on :

Subscribe to: Posts (Atom)


Sunday, August 23, 2009

MELA - Speculative Second Half 2009 Stock

MELA had a very interesting article in Barrons this weekend. The success of this stock will depend on FDA approval, which is due by the end of the year. It is an all or nothing trade (FDA approval stock could go up 50%, FDA denial stock would tank), but one worth researching. Here is the article.

Taking Aim at Skin Cancer By NEIL A. MARTIN

If approved by the FDA, the handheld MelaFind device made by Electro-Optical Sciences will revolutionize the way patients are screened for skin cancer. Look for earlier detection and fewer unnecessary biopsies. Video: Taking Aim at Skin Cancer


ONE OF THE MOST CRITICAL decisions a dermatologist can make is whether a mark on a patient's skin might be melanoma, the deadliest form of skin cancer. Until now, doctors have been forced to rely largely on their own vision, sometimes aided by a dermascope -- a hand-held magnifying glass with a light to illuminate the skin area -- to decide whether a spot or wart merits a biopsy. It involves a lot of guesswork -- and untold numbers of unnecessary biopsies.

"Skin cancer is approaching epidemic proportions," says Dr. Joseph V. Gulfo, chief executive of EOS. He thinks the company's new tool will boost the rate of early detections and reduce unnecessary biopsies.

A small Irvington, N.Y.-based medical device maker may have a better approach. Electro-Optical Sciences (ticker: MELA) has developed a computer-assisted device, currently under expedited review by the Food and Drug Administration, that could revolutionize the way doctors screen patients for cancer, and transform the Nasdaq-listed firm into a powerhouse in medical devices. If all goes according to plan, its shares could surge at least 50%.

The device, called MelaFind, consists of a hand-held imaging "gun" that emits 10 different wavelengths of light to capture images of suspect pigmented skin lesions. Because MelaFind can see where the clinician cannot -- up to 2.5 millimeters below the skin's surface -- it is expected to help catch melanomas much earlier, without the need for as many biopsies, which is good news for most patients fearful about body scarring from the procedure.


Right now, for every 30 or 50 biopsies they order up, most doctors find just one case of melanoma. The hope for MelaFind is that it will more frequently rule out melanoma before a biopsy is performed, thanks to a database of some 9,000 pigmented skin lesions. Dermatologists say it could reduce to about seven the number of biopsies performed for finding one case of melanoma.

"There will still always be the need for the experience and judgment of the dermatologist," says Doris Day, Assistant Professor of Dermatology at the NYU Langone Medical Center. "But this is a very welcomed and useful additional tool in helping us identify melanomas with greater accuracy."


MelaFind comes none too soon. Melanoma is the deadliest form of skin cancer, responsible for killing one person an hour and accounting for 80% of all skin cancer deaths. It is also the fastest growing, with over 150,000 new cases reported annually in the U.S., partly the result of excessive sun-worshiping. Hundreds of thousands of other patients visit doctors out of fear that a mole or wart might be melanoma, experts say.

"Skin cancer is approaching epidemic proportions," asserts Joseph V. Gulfo, EOS's chief executive. "Early detection is the key to survival. But medical tools to help doctors detect the malignancy have been lacking, at least until now. We believe we have found the answer in MelaFind."

THE ACCURACY OF MELAFIND'S analysis was borne out by a pivotal Phase 3 study last February. Conducted at seven locations across the U.S., the study included 1,831 pigmented skin lesions from 1,383 patients, making it the largest prospective study conducted in melanoma detection. MelaFind's specificity, or ability to accurately rule out the disease, was 2.5 times greater than that of dermatologists. The company's volatile common shares skyrocketed 80%, from $3.53 to $6.36, the day the results were announced. They've lately been trading at $7.68.

"The device has the potential to save lives like nothing we have seen in this field," says Day, who has no connection to Electro-Optical Sciences. "With the incidence of melanoma on the rise, the machine may be that much more important for the everyday practice of dermatology."


The company has already won some big fans on Wall Street. "Once the general public catches on about the ease, simplicity and accuracy of the instrument and the added benefit of avoiding unnecessary biopsies, EOS' business will shift to a higher gear," says Jeb Besser, portfolio manager with Manchester Management, a Boston hedge fund that has held EOS' shares since it went public in 2005.

Roth Capital Partners analyst Matt Dolan figures sales of the devices could hit $10 million the first year, then climb to $40 million.


Nasdaq-listed Electro-Optical Sciences is taking some of the guesswork out of the way doctors detect melanoma. Barron's Neil Martin reports.

Still, with FDA approval still pending, the stock is clearly speculative. The company now has no product on the market, no revenues and no earnings. It has had to rely on dilutive equity financings, including a $15 million deal a month ago. It now has about $21 million of cash, enough to last more than a year, given its current quarterly cash-burn rate of about $4-million-to-$5 million.

"When dealing with the FDA, there is never a sure thing, but this is probably as close to that as you are going to get," says analyst Dalton Chandler with Needham Securities. "In addition to expedited review, which means a decision within 180 days, the company has additional clinical data that look compelling and will be presented to a panel of dermatological experts in a special FDA panel meeting, probably sometime this fall.

The Bottom Line:

If MelaFind passes FDA muster, medical device maker ESO could see its share price go from near $8 to $12.
"Best bet is formal approval by the end of the year or early 2010," say Chandler. He rates MELA a Buy with a price target of $12.

See the Article

2 comments:

ชัยรัตน์ said...

Wow! your website have the great information about stock is
.I'm sure I will be back again.

financial spread betting said...

looks like they were right

DISCLAIMER

super-trades.com is simply a blog that has information on stocks that the author Superman, likes or may trade. The author may, and usually does have positions in some of the stocks discussed on the site or in email alerts and is under no obligation to disclose the size of the position or the time that it was acquired. The author also reserves the right to buy or sell at ANY time before during or after it is mentioned on this site or an email alert, with no notice or warnings. The posts are not at all intended to be recommendations for anyone else to buy, sell, or hold. Investors should not rely on the information given by this site to make investment decisions.


No contributor of the his site is a registered investment advisor or a broker / dealer. We DO NOT recommend whether to buy, sell, or hold securities . Although we believe the information on this site to be accurate, we DO NOT GUARANTEE the accurateness and completeness of statements made regarding stocks discussed on the site or in email alerts.

The performance section provides information to the public on selected stocks profiled by this site. Past performance should not be used as an indicator of future performances. We try the make the past performance section as accurate as possible but DO NOT GUARANTEE that the information is accurate.

This web site and all email alerts sent by this site contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "expects", "will," "anticipates," "estimates," believes," or statements indicating certain actions "may," "could," or "might" occur.

If any part of this disclaimer is not clear, please take the time to consult an attorney or investment specialist. Please take caution in all investment endeavors and good luck to all.

Again, My messages are not investment advice, investment solicitation or the like. Do not take action based on my messages. I do not guarantee or make claims to the accuracy of anything I post. I may buy or sell any securities I mention at anytime, even prior to posting. It is my opinion, that individuals should perform their own due diligence before investing in any stock at anytime and not base decisions on messages posted by other individuals. Individuals should assume 100% responsibility for their own investing. My messages are for my own entertainment only. LOW FLOAT stocks in particular can be volatile and are not for new traders in my opinion. I am not a registered investment advisor in any shape or form, please do not ask me for ANY investment advice.

Welcome to super-trades.com, blog home of Superman. Purpose of this blog is for me to discuss my trades and stock ideas (As well as opinions and rants on stock market related issues). I will mention the date and price I enter. As far as exits, I always try to take half off when I have some profit and if I believe in the stock, let the rest run further. I always also use mental stop limits, at which time I would exit and minimize any losses. I do not like to give price targets unless I can support them by P/E in some way or by comparison to another stock. I just post stock trades and ideas that I believe will go higher (or lower for shorts) and the reason I believe that. Individuals should have their own strategies for managing profits and losses. My stock picks tend to NOT be daytrades at all and many take time to move. I am not an investment advisor and this blog should not be considered or followed as investment advice.